RecruitingPhase 2NCT06742892

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Studying Leukoencephalopathy with calcifications and cysts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Henlius Biotech
Principal Investigator
Hua Xiang, Dr.
Hunan Cancer Hospital
Intervention
HLX43 DOSE 1(drug)
Enrollment
90 target
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06742892 on ClinicalTrials.gov

Other trials for Leukoencephalopathy with calcifications and cysts

Additional recruiting or active studies for the same condition.

See all trials for Leukoencephalopathy with calcifications and cysts

← Back to all trials